Form 4: STERIS plc CFO Michael Tokich Executes Stock Option and Sells Shares

STERIS plc CFO Michael Tokich exercised stock options and sold 23,332 ordinary shares at an average price of $247, while also acquiring the same number of shares at $114.22.

Summary

• On September 10, 2024, Michael J Tokich, the Senior Vice President and CFO of STERIS plc, engaged in transactions involving the company's ordinary shares.
• Tokich exercised an employee stock option to acquire 23,332 ordinary shares at a price of $114.22 per share.
• Simultaneously, Tokich sold 23,332 ordinary shares at a weighted average price of $247 per share, with prices ranging from $247.00 to $247.31.
• Following these transactions, Tokich directly owns 42,930 ordinary shares and indirectly owns 3,566 ordinary share equivalents through the STERIS Corporation 401(k) Plan.
• 8,286 of the directly owned shares are restricted and will vest at various dates between October 1, 2024, and June 4, 2027.
• Tokich also holds an option to purchase 23,332 STERIS plc ordinary shares at $0.

Sentiment

Score: 6

Explanation: Neutral sentiment. The document simply reports transactions. The exercise of options and sale of shares is a common practice.

Positives

• The exercise of stock options and subsequent sale of shares indicates management's confidence in the company's value, as Tokich capitalized on the difference between the exercise price ($114.22) and the market price ($247).

Negatives

• The sale of shares by a high-ranking executive could be interpreted negatively by some investors, although it is a common practice after exercising stock options.

Risks

• While not explicitly stated, potential risks could include market fluctuations affecting the value of the remaining shares and the impact of future vesting schedules on share dilution.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the restricted shares suggests a continued commitment to the company by the executive.

Industry Context

This type of filing is standard for publicly traded companies and reflects the transactions of company insiders. It provides transparency to investors regarding the buying and selling activities of key personnel.

Comparison to Industry Standards

• Form 4 filings are a standard practice for publicly traded companies in the US, ensuring transparency regarding insider transactions.
• Comparable companies like Medtronic, Boston Scientific, and Abbott also have executives who regularly file Form 4s related to stock options and share sales.
• The details disclosed in this filing are consistent with the level of information expected in such reports.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the overall effect is likely minimal.
• Employees may view the executive's actions as a sign of confidence in the company, although the sale of shares could also raise questions.

Key Dates